Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis-Reference-Cited by-同舟云学术

Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis

Published:2022-12-24 Issue:3 Volume:136 Page:360-361
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Huang He¹²³,Chen Min⁴,Wu Wenjuan¹²³,Yang Tianhui¹²³,Liu Hao¹²³,Zhu Zhengwei¹³,Wang Wenjun¹³,Yang Sen¹²³,Ding Xian²⁵,Wang Hui²⁵,Sheng Yujun¹²³,Zhang Yaohua⁶,Li Min⁴⁵,Zhang Xuejun¹²³⁶

Affiliation:

1. Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230031, China

2. Ferry Institute of Dermatology, Hefei, Anhui 230000, China

3. Boao Super Hospital Dermatology Center, Qionghai, Hainan 571437, China

4. Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University, Suzhou Dushu Lake Hospital), Suzhou, Jiangsu 215125, China

5. Department of Dermatology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China

6. Department of Dermatology, Institute of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference5 articles.

1. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis;Gordon;N Engl J Med,2016

2. Psoriasis;Griffiths;Lancet,2021

3. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials;Griffiths;Lancet,2015

4. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study;Li;Int J Dermatol Venereol,2022

5. Body mass index influence for the personalization of the monoclonal antibodies therapy for psoriasis;Anghel;Life (Basel),2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension;Chinese Medical Journal;2024-01-09